JP2025517442A5 - - Google Patents

Info

Publication number
JP2025517442A5
JP2025517442A5 JP2024568889A JP2024568889A JP2025517442A5 JP 2025517442 A5 JP2025517442 A5 JP 2025517442A5 JP 2024568889 A JP2024568889 A JP 2024568889A JP 2024568889 A JP2024568889 A JP 2024568889A JP 2025517442 A5 JP2025517442 A5 JP 2025517442A5
Authority
JP
Japan
Prior art keywords
compound
optionally substituted
formula
compound according
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024568889A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025517442A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SG2023/050202 external-priority patent/WO2023224545A2/en
Publication of JP2025517442A publication Critical patent/JP2025517442A/ja
Publication of JP2025517442A5 publication Critical patent/JP2025517442A5/ja
Pending legal-status Critical Current

Links

JP2024568889A 2022-05-20 2023-03-28 Ｔｅａｄを標的とする化合物およびその方法 Pending JP2025517442A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10202205354V 2022-05-20
SG10202205354V 2022-05-20
PCT/SG2023/050202 WO2023224545A2 (en) 2022-05-20 2023-03-28 Tead targeting compounds and methods thereof

Publications (2)

Publication Number Publication Date
JP2025517442A JP2025517442A (ja) 2025-06-05
JP2025517442A5 true JP2025517442A5 (cg-RX-API-DMAC7.html) 2026-03-16

Family

ID=88836293

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024568889A Pending JP2025517442A (ja) 2022-05-20 2023-03-28 Ｔｅａｄを標的とする化合物およびその方法

Country Status (5)

Country Link
US (1) US20250197355A1 (cg-RX-API-DMAC7.html)
EP (1) EP4526295A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025517442A (cg-RX-API-DMAC7.html)
CN (1) CN119630646A (cg-RX-API-DMAC7.html)
WO (1) WO2023224545A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025188239A1 (en) * 2024-03-05 2025-09-12 Agency For Science, Technology And Research Pan-tead inhibitors and methods thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017053706A1 (en) * 2015-09-23 2017-03-30 The General Hospital Corporation Tead transcription factor autopalmitoylation inhibitors
EP3866798A4 (en) * 2018-10-15 2022-07-13 Dana-Farber Cancer Institute, Inc. ENHANCED TRANSCRIPTIONAL ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND THEIR USES

Similar Documents

Publication Publication Date Title
JP2015508103A5 (cg-RX-API-DMAC7.html)
JP2022541483A5 (cg-RX-API-DMAC7.html)
JP2021516231A5 (cg-RX-API-DMAC7.html)
ES2660263T5 (en) Combination of akt inhibitor compound and abiraterone for use in therapeutic treatments
JP6021805B2 (ja) 腫瘍治療剤
KR101668931B1 (ko) 항종양제의 효과 증강제
JP2022544280A5 (cg-RX-API-DMAC7.html)
JP2009534386A5 (cg-RX-API-DMAC7.html)
JP2014508804A5 (cg-RX-API-DMAC7.html)
JP2010532768A5 (cg-RX-API-DMAC7.html)
JP2017526677A5 (cg-RX-API-DMAC7.html)
CN111902417A (zh) 一种二芳基巨环化合物、药物组合物以及其用途
JP2020097577A5 (cg-RX-API-DMAC7.html)
JP2015500885A5 (cg-RX-API-DMAC7.html)
JP2021504384A5 (cg-RX-API-DMAC7.html)
JP2022554272A5 (cg-RX-API-DMAC7.html)
JP2016540811A5 (cg-RX-API-DMAC7.html)
JP2016501838A5 (cg-RX-API-DMAC7.html)
JP2021524844A5 (cg-RX-API-DMAC7.html)
JP2016525104A5 (cg-RX-API-DMAC7.html)
JP2010506919A5 (cg-RX-API-DMAC7.html)
JP2016508135A5 (cg-RX-API-DMAC7.html)
JP2019526546A5 (cg-RX-API-DMAC7.html)
CA2526989A1 (en) Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors
JP2025517442A5 (cg-RX-API-DMAC7.html)